摘要
目的探讨替格瑞洛维持服用对经皮冠状动脉介入治疗(PCI)术后急性冠脉综合征患者心肺适能、QT离散度(QTd)及可溶性低密度脂蛋白受体相关蛋白1(sLRP-1)、趋化因子调节激活正常T细胞表达和分泌因子(RANTES)水平的影响。方法选择2019年3月至2020年3月收治的88例急性冠脉综合征患者为研究对象,根据随机数字表法将其分为对照组与观察组,各44例。对照组PCI术后持续服用1年氯吡格雷,观察组PCI术后持续服用1年替格瑞洛。比较两组的治疗效果。结果治疗后1年,观察组的无氧阈耗氧量(VO_(2))、每分钟通气量/二氧化碳排出量(VE/VCO_(2))均高于对照组(P<0.05)。治疗后1年,观察组的QTd、校正QT离散度(QTcd)均低于对照组(P<0.05)。治疗后1年,观察组的sLRP-1、RANTES水平低于对照组(P<0.05)。结论替格瑞洛维持服用能改善PCI术后急性冠脉综合征患者的心肺适能与QTd、QTcd,也能调节sLRP-1、RANTES表达,值得推广。
Objective To explore the effects of ticagrelor maintenance on cardiopulmonary fitness,QT dispersion(QTd),soluble low density lipoprotein receptor related protein 1(sLRP-1)and regulated upon activation normal T cell expressed and secreted(RANTES)levels in patients with acute coronary syndrome after percutaneous coronary intervention(PCI).Methods A total of 88 patients with acute coronary syndrome admitted from March 2019 to March 2020 were selected as the research objects and divided into control group and observation group according to random number table method,with44 cases in each group.The control group continued to take clopidogrel for 1 year after PCI,and the observation group continued to take ticagrelor for 1 year after PCI.The therapeutic effects of the two groups were compared.Results One year after treatment,the oxygen consumption(VO_(2))and minute ventilation/carbon dioxide output(VE/VCO_(2))in the observation group were higher than those in the control group(P<0.05).One year after treatment,QTd and correcteqd QT dispersion(QTcd)in the observation group were lower than those in the control group(P<0.05).One year after treatment,the levels of sLRP-1 and RANTES in the observation group were lower than those in the control group(P<0.05).Conclusion Ticagrelor maintenance can improve cardiopulmonary fitness and QTd,QTcd in patients with acute coronary syndrome after PCI,as well as regulate the expressions of s LRP-1 and RANTES,which is worthy of promotion.
作者
田会君
陶豫东
赵大磊
TIAN Huijun;TAO Yudong;ZHAO Dalei(Emergency Medicine Department,Henan Provincial People's Hospital,Zhengzhou 450000,China)
出处
《临床医学研究与实践》
2023年第3期32-34,共3页
Clinical Research and Practice
关键词
替格瑞洛
经皮冠状动脉介入治疗
急性冠脉综合征
心肺适能
ticagrelor
percutaneous coronary intervention
acute coronary syndrome
cardiopulmonary fitness